title: [Osteoanabolics and the forthcoming drugs for the treatment of osteoporosis].
abstract: Osteoanabolics are bone forming agents. The first approved osteoanabolic drug for the treatment of osteoporosis is teriparatide (TPTD). In the fracture prevention trial TPTD increased lumbar spine, total hip and femoral neck BMD is significantly greater compared with placebo, and it also prevents new fractures. Differently from the antiresorptive drugs, TPTD showed positive effects on various structural indices and microarchitecture using 2D histomorphometric analyses and 3D direct measurement. The insight into bone physiopathology and the better understanding of the core mechanisms involved in the development of osteoporosis led to the development of new compounds with therapeutic potential. Among them the most promising are Cathepsin K inhibitors and anti-sclerostin drugs.
authors.forename: Simeon
authors.initials: S
authors.lastname: Grazio
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019485:Bone Morphogenetic Proteins / Q000037:antagonists & inhibitors; D056657:Cathepsin K / Q000037:antagonists & inhibitors; D005819:Genetic Markers; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control*; D019379:Teriparatide / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D005819:Genetic Markers; C422903:SOST protein, human; D019379:Teriparatide; D056657:Cathepsin K